Posted On: 01/16/2013 8:21:21 AM
Post# of 72447
While the CEO cannot yet speculate on buyout offers, we can. We have to be open and honest in our assessment of what kevetrin could be capable of. I have not been and will continue to not shy away from discussing the potential for a very large 3 figure buyout.
The notion that 51.53 is where the story ends is an incomplete painting of the picture. If this is truly to become "the flagship next generation cancer therapy" , then we need to be prepared to have a level headed and objective conversation about a much higher valuation for a buyout than 51.53. I say that with no intention of hyping or pumping, as i am a serious long term investor.
In the end, it comes down to simple concepts. If the science works as we anticipate, the numbers and the math will have to follow.
The notion that 51.53 is where the story ends is an incomplete painting of the picture. If this is truly to become "the flagship next generation cancer therapy" , then we need to be prepared to have a level headed and objective conversation about a much higher valuation for a buyout than 51.53. I say that with no intention of hyping or pumping, as i am a serious long term investor.
In the end, it comes down to simple concepts. If the science works as we anticipate, the numbers and the math will have to follow.
(0)
(0)
